# Repligen Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Repligen Corporation). ## Overview Repligen Corp. is a U.S.-based life sciences company focused on bioprocessing technologies and systems used in the manufacture of biological drugs. Its portfolio spans filtration, chromatography, process analytics and proteins products sold to biopharmaceutical companies, CDMOs and other life science customers worldwide. ## Products & services • Filtration systems and single-use fluid management products • Chromatography resins, columns and purification tools • Process analytics instruments for in-line monitoring • Protein ligands and affinity products • Bioprocessing technologies for upstream and downstream manufacturing - **Filtration products** (55%) — Single-use and reusable filtration technologies used in upstream and downstream bioprocessing. - **Chromatography products** (21%) — Purification products including columns and related chromatography systems for biologics manufacturing. - **Process analytics products** (11%) — Instrumentation and desktop PAT tools used to monitor and optimize bioprocess operations. - **Proteins products** (13%) — Affinity ligands and protein-based products used in purification and separation workflows. - Filtration systems and single-use fluid management products - Chromatography resins, columns and purification tools - Process analytics instruments for in-line monitoring - Protein ligands and affinity products - Bioprocessing technologies for upstream and downstream manufacturing ## Customers Repligen sells primarily to global biopharmaceutical companies, CDMOs and other life science companies that manufacture biologic drugs. These customers buy Repligen’s products to improve process efficiency, reduce contamination risk, and support development and production of monoclonal antibodies, recombinant proteins, vaccines and advanced therapies. - **Global biopharmaceutical companies** (primary) — Buy filtration, chromatography and analytics tools for biologics production and process optimization. - **CDMOs** (primary) — Buy integrated bioprocessing products to support outsourced manufacturing for multiple clients. - **Life science integrators** (secondary) — Buy across franchises to build connected unit operations and complete bioprocess workflows. - **Diagnostics companies** (secondary) — Buy selected products and technologies where bioprocessing or related applications overlap. - **Laboratory researchers** (emerging) — Buy certain products for research and development workflows rather than commercial manufacturing. - Global biopharmaceutical companies manufacturing biologic drugs - CDMOs that run outsourced development and production campaigns - Life science integrators building end-to-end bioprocess workflows - Researchers and diagnostics customers using selected product lines - Customers buy to improve yield, flexibility and contamination control ## Geography Repligen operates globally from its headquarters in Waltham, Massachusetts, with offices and manufacturing sites in the United States, Europe and Asia. Revenue is geographically diversified, with North America representing 49%, Europe 34% and APAC plus Rest of World 17% in 2025, reflecting broad exposure to global biologics manufacturing. - **North America** (49%) - **Europe** (34%) - **APAC & Rest of World** (17%) - Headquartered in Waltham, Massachusetts, United States - Manufacturing and offices span the United States, Europe and Asia - 2025 revenue mix: North America 49%, Europe 34%, APAC/ROW 17% - Global footprint supports local sales, service and technical support - Foreign currency exposure matters because revenue and costs are global ## Strategy Repligen’s strategy is to broaden its bioprocessing platform across filtration, chromatography, process analytics and proteins so customers can source more of the workflow from one supplier. The company also emphasizes integrated solutions, internal R&D and acquisitions to add differentiated technologies and deepen its position in biologics manufacturing. - **Build integrated bioprocessing solutions** (medium-term) — Customers increasingly want connected unit operations rather than standalone tools. - **Expand process analytics and PAT** (short-term) — Actionable process data helps customers improve development and manufacturing efficiency. - **Broaden technology through acquisitions** (medium-term) — Acquired technologies can extend the portfolio and accelerate market access. - **Invest in commercial and manufacturing capacity** (short-term) — Global support and reliable supply are critical in regulated biologics production. - Expand from single products to integrated bioprocessing solutions - Cross-sell across filtration, chromatography, analytics and proteins - Use acquisitions to add differentiated technologies and capabilities - Invest in R&D and manufacturing capacity to support new products - Strengthen PAT and process analytics offerings for workflow insight ## Risks Repligen faces intense competition in a fast-changing bioprocessing market, where new technologies can displace existing products and customers may switch suppliers. Its global footprint also creates exposure to foreign exchange, tariffs, supply chain inflation, partner dependence, cybersecurity incidents and the risk that acquired technologies or intangible assets do not deliver expected value. - **Intense bioprocessing competition** [high] — New product introductions and alternative technologies can reduce demand for existing products. - **Foreign exchange volatility** [medium] — A large share of revenue and expenses is denominated outside the U.S. dollar. - **Supply chain inflation and tariffs** [medium] — Raw materials, logistics and trade actions can raise costs or disrupt deliveries. - **Acquisition and goodwill impairment** [high] — Acquired technology and customer relationships may not generate expected returns. - **Cybersecurity and data incidents** [medium] — Sensitive employee, IP and vendor data are stored across internal and third-party systems. - Competition can make products obsolete or pressure adoption - Global supply chains expose the company to inflation and tariffs - Foreign exchange moves affect reported revenue and margins - Acquisitions and intangibles can create impairment risk - Cybersecurity incidents can disrupt operations and damage trust ## Accounting The main accounting issues for Repligen are revenue recognition across a mix of product and royalty streams, and the valuation of acquired intangibles and goodwill. Investors should also watch foreign currency translation, because a meaningful portion of sales and costs is non-U.S. dollar denominated, and impairment testing can materially affect reported earnings if acquired assets underperform. - **Revenue recognition for products and royalties** — Can create quarter-to-quarter variability in reported revenue - **Goodwill and intangible asset impairment** — Impairment charges could materially reduce earnings and equity - **Foreign currency translation** — Affects comparability of reported results across periods - **Acquisition accounting** — Can affect amortization expense and future impairment risk - Product revenue is recognized on a mix of product shipments and deliveries - Royalty and other revenue depends on partner sales and can be variable - Acquired intangibles and goodwill require annual impairment testing - Foreign currency translation affects reported revenue and gross profit - Acquisition accounting can create large intangible asset balances --- *Last updated: 2026-04-29T04:51:47.467712+00:00*